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Abstract: Uveitis is a vision inflammatory disorder with a high prevalence in developing countries.
Currently, marketed treatments remain limited and reformulation is usually performed to obtain a
tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of
this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that
can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations
were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion com-
plexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular
modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes,
being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous
solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and
safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex
vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher
ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2
of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for
the reference formulation). Thus, these novel eye drops present high potential as a safe alternative
for uveitis treatment, as well as a versatile composition to include new drugs intended for topical
ophthalmic administration.
Keywords: tacrolimus; hydroxypropyl-β-cyclodextrin; topical ophthalmic administration; eye drops;
uveitis; PET/CT imaging
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1. Introduction
Uveitis is a sight-threatening inflammatory disorder that affects a wide range of ages
in the world population, being the main cause of 5–20% of blindness in Europe and United
States and over 25% in developing countries [1,2]. This affection can lead to other types
of complications, including cataract, increased intraocular pressure (IOP), macular edema
(ME) or glaucoma, compromising visual loss [3–5]. Therefore, it causes a great clinical
and socioeconomic impact on the life quality of patients [6–8] and early diagnosis and
treatment are important to prevent complications.
Uveitis is a recurrent and common ophthalmic disease that has an idiopathic etiology,
caused by a complication of an infection or associated with a systemic disease (infectious or
autoimmune disorder) [3,9]. The pathogenesis of uveitis is often caused by an autoimmune
response. Inflammatory cytokines promote the activation of T cells and trigger recruitment
of large numbers of circulation inflammatory leukocytes into the eye. This process may
cause irreversible tissue damage and visual impairment. Topical corticosteroids constitute
the first therapeutic line to treat the disease, but remarkable adverse effects can appear due
to continuous treatment with these drugs. The use of immunosuppressants in uveitis is
indicated in corticosteroid-refractory eye disease or after systemic side effects’ appearance.
Tacrolimus is a macrolide with a high molecular weight (804.02 g/mol) isolated from
Streptomyces tsukubaensis, with a great immunosuppressive activity (100 times more potent
than cyclosporine A) [10,11] that inhibits T cell proliferation and suppresses the release of in-
flammatory cytokines; it can theoretically be used to reduce inflammatory activity in uveitis
patients [3]. This drug has been used in different ocular diseases including corneal graft re-
jection [12–14], vernal keratoconjunctivitis (VKC) [15–17], dry eye [11,18], uveitis [5,19,20],
scleritis [21,22] or graft-versus-host disease [23–25], among others. Additionally, clinical
studies have shown tacrolimus’ high effectivity compared to other immunosuppressants
such as cyclosporine, at lower concentrations [26].
Nowadays, tacrolimus eye drops are not marketed and all its use rests in the elabora-
tion in hospital pharmacy departments (HPDs). The preparation of ophthalmic tacrolimus
formulations is limited by its poor water solubility (1–12 µg/mL) [27,28] due to the hy-
drolytic mechanism [29]. For this reason, 0.03% (w/v) tacrolimus eye drops are being
obtained by reformulation from intravenous drug presentation (Prograf®) [15]. However,
in this formulation, tacrolimus is solubilized in ethanol, containing irritating compounds
that usually cause discomfort and unpleasantness to the patient. Based on these statements,
it would be interesting to design new topical ophthalmic formulations with the lowest pos-
sible toxic potential and better tolerability. Several types of tacrolimus formulations such
as niosomes [30], nanoemulsions [5], microspheres [31], nanocapsules [32], micelles [33],
emulsions [34] or liposomes [35] have also been described by other authors. Nonetheless,
if these are not synthesized to be marketed, their elaboration in HPDs will be complicated.
The need to increase the solubility and stability of the drug becomes a task of ex-
treme necessity. There are several types of β-cyclodextrin (βCD) derivatives, although
most of them have not been authorized or there are not enough preclinical studies to
support their use at the topical ophthalmic level [36]. Some β-cyclodextrins have been
used by other authors as complexing agents with several drugs [27,37,38]. The oligosac-
charide 2-hydroxypropyl-β-cyclodextrin (HPβCD) is a cyclic oligosaccharide formed by
seven units of α-1,4-linked glucose and a hydroxypropylated group, with a lipophilic
central cavity and a hydrophilic outer surface. The rigid doughnut-shaped structure makes
it a natural complexing agent, being able to form inclusion complexes with several drugs,
where their structure (or part of it) may fit in the cyclodextrin cavity [39]. The complex-
ation between drugs and cyclodextrin affects many drugs’ physicochemical properties,
including their chemical stability and aqueous solubility [39]. Therefore, this hydrophilic
cyclodextrin derivative can form highly water-soluble complexes with lipophilic drugs, as
it happens with tacrolimus. There are few reports on the use of cyclodextrins to improve
the pharmaceutical characteristics of tacrolimus [37]. However, HPβCD has been chosen
in this work due to the fact that, according to the European Medicines Agency (EMA), it
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is the safest and most appropriated cyclodextrin for topical ophthalmic administration,
proving that it was not toxic [40]; this fact becomes important when transferring research
to the clinic. Hence, there is already a commercialized formulation (Indocollyre® 0.1%
ophthalmic solution) complexing HPβCD and indomethacin [41]. The improvement of
aqueous tacrolimus eye drops is still a challenge because of its low chemical stability and
solubility in particular [27].
The aim of this work was based on the design and development of different topical oph-
thalmic formulations containing tacrolimus as an alternative to the reformulated Prograf®
intravenous solution (REF). The characterization of these tacrolimus-loaded ophthalmic
formulations incorporating the improvements that cyclodextrin (HPβCD) properties can
provide in terms of tacrolimus solubility and stability in aqueous solution was also carried
out. Cyclodextrin properties may also improve the mucoadhesive characteristics of the
formulations, leading to a retention time increase on the ocular surface. In addition, the use
of new molecular imaging techniques such as positron emission tomography/computed
tomography imaging (PET/CT imaging) was incorporated into the present study in order
to better understand the in vivo formulations’ permanence on the corneal surface. On the
other hand, the evaluation of the eye drops’ safety was necessary to verify that there were
no corneal surface alterations. Based on this background, the novelty of this work relies
on the obtention of a consistent preclinical base for a new safe, stable and bioadhesive
tacrolimus eye drop designed for appropriate preparation by HPDs. Besides, additional
goals were also pre-established such as ease of preparation, scalability from the laboratory
scale to HPDs and patient comfort improvement.
2. Materials and Methods
Tacrolimus powder was acquired from Guinama® S.L.U. (La Pobla de Vallbona, Spain),
2-hydroxypropyl-β-cyclodextrin Kleptose® HPB (HPβCD; MW = 1399 Da, substitution
degree = 0.65 molar ratio) was provided from Roquette Laisa S.A.® (Valencia, Spain),
Liquifilm® was purchased from Allergan® Pharmaceuticals Ireland (Mayo, Ireland), Bal-
anced Salt Solution (BSS®) was acquired from Alcon® laboratories (Fort Worth, TX, USA)
and Prograf® (5 mg/mL, ampoules) was purchased from Astellas Pharma S.A.® (Madrid,
Spain). Ultrapure water MilliQ® (Millipore Iberica; Madrid, Spain) was used through-
out the whole work. All other chemicals and reagents were of the highest purity grade
commercially available.
2.1. Tacrolimus/HPβCD Solubilization Study
2.1.1. Phase Solubility Diagram
A phase solubility diagram was used to estimate the stability constant (K) of the
tacrolimus/HPβCD inclusion complex. The solubility measurements were carried out
following the previous work of our research group, described by Anguiano-Igea et al. [42].
This protocol was adjusted to the Higuchi and Connors phase solubility model [43]. A
solubility study was carried out by adding an excess amount of the tacrolimus powder
to MilliQ® aqueous solutions containing increasing concentrations of HPβCD (from 0 to
400 mg/mL). The vials containing these suspensions were then shaken in a VWR incubated
mini-shaker (VWR International, Radnor, PA, USA) at 25 ◦C and 250 rpm for 7 days until
reaching an equilibrium. Subsequently, each aliquot was centrifuged for 30 min at 15,300 rcf
(Centrifuge 5804 R; Eppendorf®, Hamburg, Germany) and 100 µL of the supernatant was
diluted with 400 µL of MilliQ® water (1:5 dilution) prior to measurement. Each HPβCD
concentration was assayed in quintuplicate.
Tacrolimus concentration was determined for each sample using an HPLC system
(Agilent 1260 series; Agilent Technologies®, Santa Clara, CA, USA) equipped with a Diode
Array Detector HS, a solvent delivery quaternary pump system, 400 bar maximum pressure
and an autosampler. The software model OpenLAB CDS 3D UV (PDA) was used for the
data processing. The analysis was performed under an isocratic method. The column
used was a Poroshell 120, EC-C18 (4.6 × 100 mm, 4 µm) and at a temperature of 60 ◦C.
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The mobile phase was water-acetonitrile (35:65 (v/v)) using a 1.5 mL.min−1 flow rate. A
210-nm wavelength was employed for the tacrolimus quantification. The volume of the
injected sample was 10 µL and the retention time was 3 min. The analytical method
was validated according to International Conference on Harmonization (ICH) guideline
recommendations [44] and the mathematical adjustments were made in GraphPad Prism®
8 v.8.2.1 software (GraphPad Software, San Diego, CA, USA, 2019).
AP phase solubility types are usually observed when a drug molecule forms a complex
with more than one CD molecule, assuming a consecutive complexation. A quadratic model
equation allows the estimation of both stability constants (K1:1 and K1:2). The value of K1:2
is often lower than that of K1:1.
These constants values were calculated using the following Equation (1):
S = S0 +(K1:1·S0 + K1:1·K1:2·S0·[HPβCD])·[HPβCD], (1)
where S is the total solubility, S0 is the free drug solubility and K1:1 and K1:2 are the stability
constants of the complex tacrolimus/HPβCD. K1:1 and K1:2 values were calculated by
non-linear regression using GraphPad Prism® 8 v.8.2.1 software.
2.1.2. NMR Studies and Molecular Modeling
NMR experiments were conducted at two different temperature conditions, 278 and
298 K, on a Bruker NEO 17.6 T spectrometer (proton resonance 750 MHz) (Billerica, MA,
USA), equipped with a 1H/13C/15N triple resonance PA-TXI probe with a deuterium lock
channel and a shielded Pulse Field Gradient (PFG) z-gradient. The spectrometer control
software was TopSpin 4.0 (Billerica, MA, USA, 2020). The reported chemical shifts are
referenced to the lock deuterium solvent. Spectra were processed and analyzed using
Mestrenova v14.0 software (Mestrelab Research S.L., Santiago de Compostela, Spain, 2019).
One-dimensional saturation transfer difference 1H spectra (STD) [45] were measured.
The experiment consisted of a selective saturation pulse train, a WET selective solvent
suppression module and a 90-degree hard-pulse followed by fid (free induction decay)
acquisition. The selective saturation consisted of a train of soft Gaussian-shaped pulses of
50-ms duration with a 1-ms interpulse delay. The selective saturation was applied during
2 s at a specific frequency of the 1H spectrum, covering a region of the spectrum of ± 125 Hz
around the chosen frequency (i.e., ± 0.17 ppm in a 750 spectrometer). The STDoff saturation
was applied at 20 ppm. The STDon saturation was applied at the frequency of one specific
signal of tacrolimus separated by more than 300 Hz from any signals of the HPβCD. The
STDon and STDoff scans were measured in alternate scans and subtracted by the phase
cycling, providing the subtracted STDoff-on spectra. Three STD spectra were obtained by
STDon saturation of the tacrolimus signals at 6.30, 6.12 and 2.12 ppm, respectively. Each
spectrum was acquired in 15 min with 128 scans and a 6.75-s total scan duration consisting
of a 2-s pre-scan d1, a 2-s STD saturation time and a 2.75-s fid acquisition.
Molecular modeling was also performed to have an orientation of which is the most
likely interaction between tacrolimus and HPβCD molecules using an MM+ force field
in HyperChem®. The HPβCD used in this work (Kleptose® HPB) was a mixture of
hydroxypropylated-β-CDs with a substitution mean degree of 0.65 (0.58–0.68; a mean of
4.2 hydroxypropyl groups per cyclodextrin molecule). An HPβCD molecule type with
an average of four hydroxypropyl groups per native CD unit was used to obtain the
molecular model.
2.1.3. Vehicle Solubility Study
In addition to conducting a MilliQ® water solubility study, it was studied whether
the tacrolimus solubility varied in different media in which the final tacrolimus eye drops
could be formulated. The tacrolimus solubility was tested in two different vehicles besides
MilliQ® water, these being BSS® and Liquifilm®.
Three HPβCD proportions (20%, 30% and 40% (w/v)) were used sixfold with each
vehicle and a two-way ANOVA was subsequently applied to compare the formulations’
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solubility and to check for significant differences among them. This assay was carried out
as a way to select the formulations to be tested for further analysis.
2.2. Formulation Preparation Procedure
The 2-hydroxypropyl-β-cyclodextrin (HPβCD) solutions were prepared by dissolving
them in the two vehicles studied in the previous assay (BSS® and Liquifilm®); these were
selected because they are ophthalmic vehicles that are frequently used in HPDs for eye
drop formulation. BSS® is an isotonic salt solution for use in irrigating eye tissues, with pH
7.5 and a ≈300 mOsm/kg osmolality [46]. Furthermore, Liquifilm® is an artificial eye tear
that contains 1.4% polyvinyl alcohol (PVA) and a benzalkonium chloride preservative as
well as different salts [47].
Based on the vehicle solubility study results (see Section 2.1. Tacrolimus solubiliza-
tion with HPβCD results), the HPβCD and tacrolimus concentrations were chosen. The
formulations were labeled as TBS 20 (20% (w/v) HPβCD and 0.01% (w/v) of tacrolimus in
BSS®), TBS 40 (40% (w/v) HPβCD and 0.02% (w/v) of tacrolimus in BSS®), TLI 20 (20% (w/v)
HPβCD and 0.01% (w/v) of tacrolimus in Liquifilm®) and TLI 40 (40% (w/v) HPβCD and
0.02% (w/v) of tacrolimus in Liquifilm®) (see Table 1). Once the cyclodextrin was dissolved,
tacrolimus powder was added under magnetic stirring (>750 rpm) until all the tacrolimus
powder was dissolved.
Table 1. Tacrolimus eye drops composition.
Formulation
Composition
HPβCD (w/v, %) Tacrolimus (w/v, %) Vehicles
TBS 20 20 0.01 BSS®
TLI 20 20 0.01 Liquifilm®
TBS 40 40 0.02 BSS®
TLI 40 40 0.02 Liquifilm®
REF - 0.03 Liquifilm®
The reference formulation was prepared just as it is formulated in an HPD; a mixture
of 0.03% (w/v) tacrolimus in Liquifilm® was prepared by a Prograf® (5 mg/mL) intravenous
ampoule dilution as it was done in previous work [15], instead of using the tacrolimus
powder. All formulations were kept under refrigeration conditions (4 ± 2 ◦C) to avoid
degradation processes of the drug when they were prepared. Tacrolimus concentrations
used in clinical practice are very variable (0.005% to 0.1% range) [11,17,48,49]; it should be
noted that the selection of the designated tacrolimus concentration has been carried out on
the basis of previous experimental studies (see Section 2.1.3. Vehicle solubility study).
2.3. Optimization Procedure: Tacrolimus Solubilization Time
The purpose of this assay was to know the required tacrolimus solubilization time in
the eye drops so that when the formulation has to be replicated in an HPD, the drug will
not be removed when performing the sterilizing filtration, ensuring quality, final product
efficacy and patient safety.
This study was designed to establish the minimum stirring time of the tacrolimus
powder to achieve the desired concentration in the solution media. HPβCD dissolution
was carried out in triplicate (10 mL per formulation), and the amount of tacrolimus powder
was added once all the cyclodextrin was dissolved. The solutions were shaken in a Cimarec
I multipoint magnetic stirrer (ThermoFisher® Scientific; Waltham, MA, USA) at 900 rpm
and 30 ◦C during the whole study period.
At predetermined times (24, 40, 48, 67, 72, 90 and 96 h), samples were collected
without stopping the stirring, thus achieving the dissolution homogeneity. Samples were
centrifuged (Centrifuge 5804 R; Eppendorf®, Germany) at 15,300 rcf and 25 ◦C for 30 min
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to remove any undissolved particles. Subsequently, 400 µL of the supernatant was taken to
measure the tacrolimus concentration by HPLC (Agilent 1260 series; Agilent Technologies®,
Santa Clara, CA, USA) with the method described above (see Section 2.1.1. Phase solubility
diagram). The tacrolimus concentration was corrected in each measure according to the
volume that was left (0.5 mL less in each sample). Resulting data were compared and a
statistical analysis was performed using a two-way ANOVA to analyze the influence of the
solubilization time and the composition of the formulations. The analysis was carried out
using GraphPad Prism® 8 v.8.2.1 software.
2.4. Physicochemical Characterization
2.4.1. pH and Osmolality Determination
The osmolality measurements were performed with an OsmoSpecial 1 osmometer
(Astori Tecnica®; Poncarale, Italy), while the pH was measured using a pH meter (HI5221
HANNA®, Italy) at 25 ± 0.5 ◦C. Each determination was carried out in triplicate.
2.4.2. Surface Tension Determination
Surface tension at the surface-to-air interface was measured using the du Nöuy ring
method [50]. A Lauda TD1 tensiometer (LAUDA Scientific GmbH®, Lauda-Königshofen,
Germany) fitted with a platinum ring (2-cm diameter) was used to measure the surface
tension of the tacrolimus formulations. A platinum du Nöuy ring was immersed into the
liquid and then lifted to obtain tension values. The measurements were made at room
temperature.
All glassware used for the surface tension measurements was washed with MilliQ®
water and then dried in a clean oven before use. The platinum du Nöuy ring was washed
with alcoholic KOH, rinsed in MilliQ® water and flamed until red-hot before each mea-
surement. The determinations were carried out in triplicate.
2.4.3. Squeezing Force Determination
The squeezing force test evaluates the force needed to dispense a drop from 5-mL
polypropylene eyedropper bottles that are commonly used in HPDs. A comparison of
the cyclodextrin formulations with each other and between the reference one was made
in order to assess the presence or absence of significant differences depending on their
composition.
This method was performed following the method established by Charles H. Cox,
with minor modifications [51], in a Shimadzu® texturometer (Kyoto, Japan). Figure 1
describes in detail the protocol followed to obtain the squeeze force measurements. The
eyedropper bottle containing 5 mL of formulation was placed on a plate with a 45◦ incli-
nation just below the load cell (1000 N maximum force). Test parameters were set after
the method optimization; the upper probe moved down at a speed of 0.5 mm/s and
an assessment of the required force to spill one drop of the formulation was performed.
Five eyedropper bottles of each formulation were tested in quintuplicate (25 measurements
per formulation). A one-way ANOVA was carried out to find out if there were significant
differences. Tukey´s multiple comparisons test was subsequently performed in order to
compare all formulations.
2.5. Corneal Mucoadhesion
Tacrolimus formulations’ mucoadhesion was measured following a method designed
and developed by our research group using a Shimadzu® texturometer [52]. Corneal
bioadhesion was used to quantitatively determine the interaction between the formulation
and the corneal bovine surface. As presented in Figure 2, fresh bovine corneas were
adjusted to a cornea mold made of clay and subsequently fixed to a texturometer load cell
(20 N maximum force). Formulations were dropped in a glass bottle (40 mm diameter,
20 mm height) and placed in the lower part of the analyzer.










Figure 1. Scheme of the squeezing force determination.
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Corneas were immersed 2 mm deep into the formulation at a 1 mm/s speed and force
data (N) were obtained. Then, corneas were kept in touch with the formulation for 30 s,
and just after returning to the starting point at a 1 mm/s speed, work (mJ) was measured.
Mucoadhesion work was calculated from the area under the curve (AUC) of the force–
displacement curve. All method parameters were previously studied and subsequently
applied. Each measurement was carried out in triplicate.
2.5.1. Bovine Corneal Opacity and Permeability Test (BCOP)
The Bovine Corneal Opacity and Permeability test (BCOP) is an organotypic assay
used to identify potential ocular corrosives and severe irritants. This method was carried
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out using slaughterhouse materials (fresh bovine corneas), allowing the animal replacement
compliance and avoiding the use of laboratory animals. This assay was founded on
the method established by Tchao et al. [53] and adapted by Gautheron et al. [54], with
minor modifications.
Freshly excised eyes were obtained from a local slaughterhouse and transported to
the laboratory in optimal conditions. A macroscopic inspection of the eyes was performed,
and only free-of-defects corneas were dissected and used for the test. Fresh corneas were
mounted in Franz diffusion cells with the corneal epithelial surface facing upwards, divid-
ing the two different chambers of the diffusion cell (donor and receptor). A thermostatic
bath with a controlled temperature (37 ± 2 ◦C) and under stirring (100 rpm) during the
whole assay was used to incubate all Franz diffusion cells.
Corneal opacity changes were measured by two different techniques, these being
photometry and UV–Vis spectrophotometry. Photometry was assessed using a luxmeter
(Gossen® Mavolux 5032C USB; Nürnberg, Germany), where corneas were placed between
two cylindrical supporting black holders (fabricated with polylactic acid filaments using
a 3D printer, Witbox® BQ, Madrid, Spain) and illuminated with a pipe light (Olympus®
Highlight 200, Tokyo, Japan) with fixed brightness values [55]. Corneal transparency was
measured in transmittance values by UV–Vis spectrophotometry (from 200 to 800 nm),
allowing the light to pass through the corneas, from the source to the receiver of the
spectrophotometer (Cary 60 UV-Vis, Agilent Technologies®; Santa Clara, CA, USA). Each
formulation was tested in triplicate.
The following protocol was performed for formulations’ addition and opacity mea-
surements: (I) determination of the initial opacity values for freshly excised corneas by
photometry and UV–Vis spectrophotometry; a corneal blank was made before photom-
etry determination in order to remove basal light, while the cornea itself was used as a
blank (800-nm wavelength) before spectrophotometry determination; (II) addition of 1 mL
Phosphate-Buffered Saline (PBS) into the donor chamber of the vertical diffusion cells and
cornea incubation were performed for 10 min, followed by opacity determination; (III)
an amount of 1 mL of the formulation was then added to the upper chamber for 10 min,
followed by its subtraction and further addition of PBS for 120 min; after this time, the
opacity determination was repeated.
Once the opacity was measured, the same corneas were used to evaluate the corneal
permeability changes, so 1 mL of 0.4% (w/v) fluorescein aqueous solution was added in the
donor compartment, keeping in touch with the corneal epithelium side. After 90 min, the
corneal permeability determination was evaluated by measuring the optical density (OD)
in the medium (PBS) of the lower compartment at a 490-nm wavelength.
An in vitro irritation score (IVIS) can be calculated with the measurements of corneal
opacity and permeability. The IVIS was determined by the following Equation (2):
IVIS = mean opacity value + (15 × mean permeability OD490 value), (2)
2.5.2. Hen’s Egg Test on the Chorioallantoic Membrane (HETCAM)
The hen’s egg test on the chorioallantoic membrane (HETCAM) assay is one of the
new organotypic models that allows the identification of irritative reactions, and it has
become the international standard assay for acute eye irritation and corrosion (OECD TG
405, 2002; EC B.5). This assay was performed to evaluate possible acute ocular irritation
caused by the present tacrolimus formulations.
Fertilized Broiler eggs (50–60 g weight) were obtained from the regional hatchery
technology center and incubated for nine days in specific conditions (37 ± 0.5 ◦C and 65%
± 5% RH). The eggs were automatically rotated in an automatic rotational incubator every
2 h until the eighth day, where rotation was stopped, and the eggs were kept in the axial
position during 24 h for the proper placement of the chorioallantoic membrane (CAM). The
protocol used was adapted from the procedure described by Spielmann and Liebsch [56].
At the ninth day of incubation, embryonated eggs were opened by their upper part
with a tiny drill (Dremel®, Madrid, Spain) and the inner membrane was moistened with
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0.9% (w/v) NaCl aqueous solution so that it could be removed later. Briefly, 300 µL of 0.9%
(w/v) NaCl solution (negative control), 0.1% (w/v) NaOH solution (positive control) and
tacrolimus formulations (TBS 20, TLI 20, TBS 40, TLI 40 and REF) were directly instilled
onto the CAM (2 eggs per compound). The membrane was observed over a 5-min period
using an Olympus® SZ61TR Stereomicroscope and Olympus® CellSens Entry software.
Hemorrhage, lysis and coagulation of the CAM were measured; these reactions can be
quantified through an irritation score (IS) following the Kalweit et al. criteria [57]. Based
on this, they can be classified as follows: 0–0.9, no irritation; 1–4.9, slight irritation; 5–8.9,
moderate irritation; and 9–21, severe irritation.
2.6. Stability Study
The stability study was only carried out with the formulations containing the greatest
amount of drugs due to the fact that all the formulations have the same composition, the
formulations with 40% (w/v) HPβCD being the most representative, as they have a greater
amount of the components with activity and based on the clinical common usability and
the drug concentration similarity at present.
Based on this, both formulations (TBS 40 and TLI 40) were aseptically prepared under
laminar air flow. Briefly, 2 mL of each gel was conditioned into a 5-mL polypropylene
eyedropper, previously sterilized, and the dropper was closed with a polypropylene cap.
Three batches of each formulation were prepared and subjected to a double filtration with
0.22-µm PES (polyethersulfone) filters.
The stability of each eyedrop was studied in unopened multidose eyedroppers for
4 months at three different temperature conditions: in refrigeration (4 ± 2 ◦C), at room
temperature (25 ± 2 ◦C) and at oven temperature (40 ± 2 ◦C), protected from light expo-
sure in all cases. Three units per formulation were subjected to tacrolimus quantification,
osmolality determination, pH measurements and microbiological control growth at prede-
termined times (0, 15, 30, 45, 78 and 120 days). All samples were also visually inspected for
any macroscopic changes (e.g., color, turbidity and precipitation).
2.6.1. Quantification of Tacrolimus Amount
The determination of tacrolimus was performed as previously mentioned (see Section 2.1.1.
Phase solubility diagrams). Refrigerated and accelerated samples were kept at room tem-
perature for 20 minutes before quantification. Each sample was assayed in triplicate. The
analytical method was validated according to International Conference on Harmonization
(ICH) guideline recommendations [44].
2.6.2. Osmolality, pH and Microbiological Control Growth
The pH and osmolality measurements were performed following the same experimen-
tal procedure previously described (see Section 2.4.1. pH and osmolality determination). In
order to study the microbiological stability, 1 mL of each formulation was added in blood
agar plates, Sabouraud/Chloranphenicol agar plates and liquid thioglycate medium plates.
These samples were grown at 37 ◦C for predetermined periods (48 h, 15 days and 10 days,
respectively). Once each incubation period ended, microbiological growth was observed
and determined.
2.6.3. Statistical Analysis
Pharmaceutical Codex [58] has established the margins of the expiration period of
the formulations as being once the concentration of active ingredient is reduced by 10%
concerning the initial concentration. The percentage of unaltered drug versus time was
fitted to a first order kinetics using GraphPad Prism® 8 v.8.2.1 software and the degrada-
tion constant (K), expiration time (t90) and determination coefficient (R2) were calculated.
pH and osmolality monitoring were performed to observe the presence of any changes.
Microbiological stability was considered adequate when no microbial growth was pro-
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vided in the cultured samples. The presence of any abnormal macroscopic particles in the
formulations was not considered acceptable.
2.7. In Vivo Evaluation of the Residence Time on the Ocular Surface
In vivo studies were carried out on male Sprague-Dawley rats with an average weight
of 250 g supplied by the animal facility at the University of Santiago Compostela (Spain).
The animals were kept in individual cages under controlled temperature (22 ± 1 ◦C) and
humidity (60 ± 5%), with day–night cycles regulated by artificial light (12/12 hours) and
feeding ad libitum. The animals were treated according to the ARVO statement for the
use of animals in ophthalmic and vision research as well as the approved guidelines for
laboratory animals [59,60]. Experiments (idis12072017) were approved by the Institutional
Committee of the Health Research Institute of Santiago de Compostela (IDIS) following
the Galician Network Committee for Ethics Research, the Spanish and European Union
(EU) rules (86/609/CEE, 2003/65/CE, 2010/63/EU, RD 1201/2005 and RD53/2013).
The positron emission tomography (PET) and computed tomography (CT) procedures
for conducting the radiolabeling of the formulations and the quantitative ocular perma-
nence study were described in our previous works [15,61,62]. Briefly, PET and CT images
were acquired using the Albira PET/CT Preclinical Imaging System (Bruker Biospin®;
Woodbridge, Connecticut, USA). Anesthetized animals (2.5% (v/v) isoflurane/oxygen)
were positioned into the imaging bed, monitoring the respiration frequency. Afterward,
7.5 µL of each tacrolimus formulation, previously radiolabeled with 18F-fluorodeoxyglucose
(18F-FDG), was instilled into the conjunctival sac of both eyes using a micropipette. The
administered radioactivity was 0.20–0.25 MBq per eye. After the instillation, static PET
frames at different times (0, 30, 75, 120, 240 and 300 min) were acquired as a way to evaluate
the pharmacokinetics behavior. To prevent the rats from scratching their eyes by removing
the instilled formulations, an Elizabethan collar was placed between PET studies. Two
animals (4 eyes) were tested for each formulation in order to accomplish the 3Rs regulatory
frameworks [63].
Image analysis was performed using the Amide´s Medical Image Data Analysis
Tool [64]. Regions of interest (ROIs) were manually drawn for the different frames by
delimiting the total radiotracer uptake of each eye using a spherical volume of 1767.1 m3
(15 × 15 × 15 mm). The radiotracer uptake over time was corrected by the radioisotope
decay (18F half-life: 109.7 min). Subsequently, a clearance rate for each formulation was
obtained in terms of the ocular remaining radioactivity uptake over time after instillation.
The data were fitted using a non-compartmental analysis in order to calculate the elim-
ination constant (K), the half-life (t1/2) and the zero and first moment pharmacokinetic
parameters, area under curve (AUC0∞) and mean residence time (MRT) using GraphPad
Prism® 8 v.8.2.1 software.
3. Results and Discussion
3.1. Tacrolimus/HPβCD Solubilization Study
The phase solubility diagram of tacrolimus in aqueous HPβCD solutions at 25 ◦C is
shown in Figure 3. The resulting profile indicates an AP-type diagram that shows a positive
deviation from characteristic linearity, this being supported by previous studies [27,37].
Thus, the formation of a soluble complex in the aqueous media with the formation of
high-order drug/CD complexes at high cyclodextrin concentrations is assumed. It must
be taken into account that the formation of 1:1 and 1:2 drug/CD complexes and both K1:1
and K1:2 stability constants were calculated. Tacrolimus aqueous solubility in the absence
of cyclodextrins was 4 ± 0.67 µg/mL, and K1:1 and K1:2 values were 143.1 ± 10.3 and
2.1 ± 0.6 M−1, respectively.
The low values of stability constant indicate that tacrolimus and HPβCD interactions
were weak, especially in the 1:2 complex. The main reason for this weak interaction
between the drug and cyclodextrin may be the high molecular weight and the complex
molecular structure of tacrolimus that hampered an adequate adaptation to the cyclodextrin
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cavity. This study was made only with HPβCD because according to the EMA, it is the
safest cyclodextrin and most appropriated for topical ophthalmic administration together
with sulfobutylether-β-cyclodextrin (SBEβCD), proving that it is not toxic [40]. This fact
becomes important when transferring research to the clinic. Thus, NMR studies were
performed in order to study the part of the drug and cyclodextrin structure involved in the
complex formation.
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Figure 3. The phase solubility diagram of tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) at
25 ◦C in purified water. Stability constants values represent the mean ± SD (n = 5).
The intermolecular interaction between tacrolimus and HPβCD in aqueous solution
was studied by NMR in the tacrolimus/HPβCD mixture prepared in D2O at a 200 mM
HPβCD concentration and tacrolimus saturation (0.2 mM). The 1H spectrum of the mixture
at 278 K (Figure 4a) shows resonances at the chemical shifts expected for tacrolimus signals
(a reference spectrum of pure tacrolimus in MeOD is given in Figure 4d) with a considerable
broadening, a possible indication that the tacrolimus is forming a large aggregate or
self-aggregate in the water solution due to its very low polar characteristics. To test for
binding between the tacrolimus and HPβCD in the mixtures, a one-dimensional saturation
transfer difference spectrum (STD) was used, being a well-known NMR technique for
screening ligands binding to protein receptors [45,65]. STD spectra were measured with
auto-subtraction of alternate scans acquired with off- and on-irradiation providing the
so-called STDon-off spectra [45]. In these STD spectra, the on-irradiation was placed in a
certain proton signal of tacrolimus that is sufficiently separated in frequency from any
HPβCD signal to prevent them being directly saturated. Three STDon-off spectra were
measured at 278 and 298 K under otherwise identical conditions. Interestingly, only the
STDon-off spectra measured at the lower temperature (278 K, but not at 298 K) provided
STD signal responses for the HPβCD species, as can be seen in Figure 4b–d. This is due to
the partial transfer of saturation from the tacrolimus signal being irradiated to the HPβCD
resonances, which reflects that there is a binding equilibrium between these two molecules
(Figure 4). The fact that the STD responses are only obtained in the spectra measured at
278 K and not at 298 K could indicate that there is low affinity between the two molecules
at 298 K (i.e., binding equilibrium with Kd > 10 mM [66]), while the affinity is notably
enhanced at 278 K (i.e., Kd < 1 mM [66]). Overall, these NMR results strongly suggest
that tacrolimus is forming a large self-aggregate in the water solution and it is partially
s lubilized by formi g a complex with HPβCD.
The molecular modeling of the tacr limus/HPβCD interaction of 1:1 and 1:2 stoichiom-
etry inclusion complexes is shown in Figure 5. The molecular docki g studies indicate the
higher probability of tacrolimus inclusion by its 4-hydroxy-3-methoxycyclohexyl group.
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Figure 5. Molecular modeling of tacrolimus/HPβCD interaction. Molecular modeling of the 1:1 (a) and 1:2 (b) complex
structures for tacrolimus and HPβCD obtained by manual docking and energy minimization using an MM+ force field
in HyperChem®.
The effect of BSS and Liquifilm® (as ophthalmic vehicles) on the complexation was
also studied (Figure 6). Hence, a vehicle solubility study was experimentally carried out
to determine the tacrolimus behavior with increasing HPβCD concentration media. As
presented in Figure 6, a proportional increase in the tacrolimus solubility was observed
by increasing the amount of cyclodextrin included into the vehicle. A two-way ANOVA
was subsequently performed to compare all the media and assess the inclusion complexes’
formation. The resulting data showed no significant differences between the 20% (w/v) and
30% (w/v) HPβCD in all vehicles; nonetheless, statistically significant differences (α < 0.05)
were found between 20% (w/v) and 30% (w/v) HPβCD solutions compared to the 40% (w/v)
HPβCD solutions in all the vehicles. According to these results, the 30% (w/v) HPβCD
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formulations were discarded and only 20% (w/v) and 40% (w/v) HPβCD solutions were
used in further studies.
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Figure 6. Tacrolimus solubility with 20%, 30% and 40% (w/v) of HPβCD in B lanced Salt Solution
(B S®) and Liquifilm® vehicles. Statistical analysis: two-way ANOVA fo lowed by T s ultiple
comparison test (* α < 0. 5 compared with 20% (w/v) and 30% (w/v) Pβ i ll i l ); one-
way ANOVA followed by Tukey´s multiple comparison test (** α < 0.05 compared with the other
two vehicles (MilliQ® water and BSS®).
The resulting data also showed significant differences (α < 0.05) among all the for-
mulations for both PβCD concentrations. Tukey´s multiple comparison test was then
perfor ed, si ificant differences wer also observ d betw en Liquifilm® and the ot r
two vehicles (MilliQ® water and BSS®) but there w non found between MilliQ® water
and BSS®. The tacrolimus sol bility in Liquifilm®-dilute formulations may be attributed
to th ternary complex f rmation (tacrolimus/HPβCD/PVA), increasing tacrolimus s lu-
bility by a synergistic solubilization effect [67].
Formulations were su ce sfu ly prepared by an i cl sion c lex di solution tech-
nique. Tacrolimus was incorporated into the HPβCD hydrophobic cavity, leading to an
increase in its water solubility. The solubilization time was determined in order to know
the time nece sary to completely di solve the required dose (Figure 7).
The time needed to prepare the aforementioned tacrolimus topical ophthalmic for-
mulations will be a key preparation parameter in HPDs. As presented in Figure 7, 20%
(w/v) HPβCD formulations containing tacrolimus reached 100% solubilization in a 90-h
period, while 40% (w/v) HPβCD formulations containing tacrolimus showed different
solubilization time, being quicker for the TLI 40 (72-h period, against the 90-h period for
TBS 40). A two-way ANOVA was further carried out to study differences in tacrolimus sol-
ubilization time among the formulations. The resulting data showed statistically significant
differences between TLI and TBS formulations (α < 0.05) from 40 h onwards. Nevertheless,
no differences were found between TLI 20 and TLI 40, nor between TBS 20 and TBS 40.
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Table 2. pH, osmolality and surface tension results of tacrolimus/HPβCD formulations. 
Formulations 
pH Osmolality (mOsm/kg) Surface Tension (mN/m) 
Mean SD Mean SD Mean SD 
TBS 20 7.036 0.021 359.3 5.86 54.63 0.93 
TLI 20 6.986 0.005 283.6 2.52 58.46 1.10 
TBS 40 7.203 0.005 628 6.93 51.5 0.61 
TLI 40 6.933 0.005 383 18.08 58.43 0.21 
REF 7.3 0.014 1220.5 18.57 47.5 0.2 
Surface tension determination constitutes a key assay for a topical ophthalmic for-
mulation. Appropriate surface tension values guarantee that a formulation may be spread 
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3.2. Physicochemical Characterization
3.2.1. pH, Osmolality and Surface Tension
pH and osmolali y determinations were carri d out in order to ensure that the for-
mulations show values within the oc r physiological range. As present in Table 2, all
formulations met the pH and osmolality specifications described for topical ophthalmic
administration. These result s pport the idea that these new formulations c uld be used
without generating adverse effects in the ocular surface, compare to the control formula-
tion (REF) [15] where, despite showing a pH value within the physiological range (pH 4 to
8) [68], the osmolality values (1220.5 mOsm/kg) were four times higher than the limit value
for topical ophthalmic administration. Likewise, hypertonic topical ophthalmic formula-
tions may alter the tear osmolarity and, thus, induce ocular inflammation, as described by
Dutescu et al. [69].
Table 2. pH, osmolality and surface tension results of tacrolimus/HPβCD formulations.
Formulations
pH Osmolality (mOsm/kg) Surface Tension (mN/ )
Mean SD Mean SD Mean SD
TBS 20 7.036 0.021 359.3 5.86 54.63 0.93
TLI 20 6.986 0.005 283.6 2.52 58.46 1.10
TBS 40 7.203 0.005 628 6.93 51.5 0.61
TLI 40 6.933 0.005 383 18.08 58.43 0.21
REF 7.3 0.014 1220.5 18.57 47.5 0.2
Surface tension determination constitutes a key assay for a topical ophthalmic formu-
lation. Appropriate surface tension values guarantee that a formulation may be spread
evenly over the entire corneal surface, ensuring the drug optimal ocular penetration and
also enhancing the comfort of the user when applying eye drops [70]. The ideal eye drop
will have a surface tension similar to the tear film fluid (42–46 mN/m) [71]. Nonetheless,
Han et al. previously studied the surface tension of commercialized ophthalmic formula-
tions and the results showed that these topical ophthalmic solutions had surface tensions
greater than that of tears (34.3–70.9 mN/m), most likely increasing the tear film stability
and allowing for a greater lubrication of the eye [72].
Therefore, in the case of the designed formulation (TBS 20, TLI 20, TBS 40 and TLI
40), he surface tension valu s were slightly higher than physiological par meters, but
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they were still at an optimal value (see Table 2). These surface tension values can be given
by HPβCD, which shows values of 54.8–57.5 mN/m in solution, as it was previously
mentioned by Saokham et al. [67]. However, the reference formulation (REF) showed
lower surface tension values than the others, being associated to the presence of ethanol in
its composition.
A one-way ANOVA was applied to determine the surface tension of each formula-
tion, and statistically significant differences were observed (α < 0.05). Tukey’s multiple
comparison test was also performed, and no statistically significant differences were found
between the TLI 20 and TLI 40 formulations, but significant differences were observed
between the rest of the formulations (α < 0.05).
3.2.2. Squeezing Force Determinations
Figure 8 show the squeezing force test results for the studied formulations. Based
on the research of Conner et al. [73], a large percentage of patients (>50%) receiving local
ophthalmic treatments reported that self-management is difficult due to the need to apply
force to the eyedropper in order to get the preparation out. Besides, high doses may cause
the patient to suffer from side effects, while underdosing may cause damage or prolonged
drug therapy. The volume and structure uniformity of the formulation drops are also
important properties to ensure accurate drug dosage and avoid treatment variability.
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Figure 8. Comparison of squeeze force (N) values among different tacrolimus formulations (TBS 20,
TLI 20, TBS 40, TLI 40 and REF). Statistical analysis: one-way ANOVA followed by Tukey´s multiple
com arison test (* α < 0.05 compared with prepared formulations).
The squeezing force test may be affected by different factors such as the formulation
viscosity, surface tension or dropper tip design [74]. Therefore, the same type of packaging
for testing was used. A one-way ANOVA was applied to determine the required force to
dispense a drop of each formulation, and statistically significant differences were observed
(α < 0.05). Tukey’s multiple comparison test was also applied, and no statistically significant
differences were found between the tacrolimus/HPβCD formulations, but significant
differences were observed between the reference formulation (REF) and the prepared
formulations (α < 0.05).
3.3. Corneal Mucoadhesion
Knowing that the mucoadhesion properties of the topical ophthalmic formulations will
give an approximate idea of the permanence time on the ocular surface, bioadhesion work
measurements were performed with the studied topical ophthalmic formulations. All data
were assessed through breaking strength (N) and bioadhesion work (mJ) measurements
(Figure 9).
Pharmaceutics 2021, 13, 149 16 of 27
Pharmaceutics 2021, 13, x 16 of 28 
 
 
significant differences were found between the tacrolimus/HPβCD formulations, but sig-
nificant differences were observed between the reference formulation (REF) and the pre-
pared formulations (α < 0.05). 
3.3. Corneal Mucoadhesion 
Knowing that the mucoadhesion properties of the topical ophthalmic formulations 
will give an approximate idea of the permanence time on the ocular surface, bioadhesion 
work measurements were performed with the studied topical ophthalmic formulations. 
All data were assessed through breaking strength (N) and bioadhesion work (mJ) meas-





Figure 9. (a) Maximum breaking strength (N) and (b) bioadhesion work (mJ) obtained for each formulation using bovine 
cornea as a substrate. Statistical analysis: (a) one-way ANOVA followed by Tukey´s multiple comparison test (* α < 0.05 
compared with TLI 20, TBS 40 and TLI 40 and ** α < 0.05 compared with TLI 20, TBS 40 and TLI 40); (b) one-way ANOVA 
followed by Tukey´s multiple comparison test (* α < 0.05 compared with TLI 20 and ** α < 0.05 compared with TLI 20 and 
TBS 40). 
A one-way ANOVA was performed to define the bioadhesion work of the studied 
formulations, and statistically significant differences were observed (α < 0.05). Tukey’s 
multiple comparison test was also applied, and statistically significant differences were 
found between the TBS 20 and TLI 20 formulations and between the REF and TLI 20 and 
TBS 40, but no significant differences were observed between the rest of the formulations 
(α > 0.05). 
The highest bioadhesion work values were obtained for the TLI 20 (0.036 ± 0.009 mJ) 
and TBS 40 (0.035 ± 0.013 mJ) formulations, and the lowest values were obtained for TBS 
20 (0.026 ± 0.008 mJ) and REF (0.023 ± 0.005 mJ). In the case of TLI 40 (0.031 ± 0.011 mJ), no 
statistically significant differences were observed compared with TLI 20 and TBS 40. It 
was observed that during the separation stage of the cornea from the formulation, a for-
mulation film remained adhered to the cornea when the load cell was lifted. It can be 
assumed, then, that the formulation interacts with the corneal surface with more intensity 
than the own cohesive forces of the formulation. Therefore, the adhesive bond fails due to 
the formulation fracture, making the viscosity and consistency play a fundamental role. 
An in vivo ocular permanence study was subsequently performed using a PET/CT 
imaging technique to confirm the bioadhesive behavior of the formulations. 
































































Figure 9. (a) Maximum breaking strength (N) and (b) bioadhesion work (mJ) obtained for each formulation using bovine
cornea as a substrate. Statistical analysis: (a) one-way ANOVA followed by Tukey´s multiple comparison test (* α < 0.05
compared with TLI 20, TBS 40 and TLI 40 and ** α < .05 compared with TLI 20, TBS 40 and TLI 40); (b) one-way ANOVA
followed by Tukey´s multiple comparison test (* α < .05 compared with TLI 20 and ** α < .05 compared with TLI 20 and
TBS 40).
A one-way ANOVA was performed to define the bioadhesion work of the studied
formulations, and statistically significant differences were observed (α < 0.05). Tukey’s
multiple comparison test was also a plied, and statistically significant differences were
found between the TBS 20 and TLI 20 formulations and between the REF and TLI 20 and
TBS 40, but no significant differences were observed between the rest of the formulations
(α > 0.05).
The highest bioadhesion work values were obtained for the TLI 20 (0.036 ± 0.009 mJ)
and TBS 40 (0.035 ± 0.013 mJ) formulations, and the lowest values were obtained for TBS
20 (0.026 ± 0.008 mJ) and REF (0.023 ± 0.005 mJ). In the case of TLI 40 (0.031 ± 0.011 mJ),
no statistically significant differences were observed compared with TLI 20 and TBS 40.
It was observed that during the separation stage of the cornea from the formulation, a
formulation film remained adhered to the cornea when the load cell was lifted. It can be
assumed, then, that the formulation interacts with the corneal surface with more intensity
than the own cohesive forces of the formulation. Therefore, the adhesive bond fails due to
the formulation fracture, making the viscosity and consistency play a fundamental role.
An in vivo ocular permanence study was subsequently performed using a PET/CT
imaging technique to confirm the bioadhesive behavior of the formulations.
3.4. Ocular Irritancy and Toxicity
Some eye irritation and toxicity assessment tests have shown considerable potential to
eliminate procedures that were historically performed by animal experimentation, such as
the Draize rabbit eye irritation test which presents one of the most criticized and contested
animal tests [75]. The efficacy of these in vitro and ex vivo procedures has been well
studied by pharmaceutical industries and some national regulatory agencies [76]. The
replacement of the Draize rabbit eye test with alternative models includes physicochemical
tests, cell and tissue culture systems or organotypic models as eye components or isolated
eyes [76–78].
The strategy to replace the Draize test by combining several animal-free methods has
raised expectations [75]. The combination of two different methods has been proposed
in this work. The Bovine Corneal Opacity and Permeability test (BCOP), which allows to
detect whether the tested compounds cause a moderate, severe or very severe irritation,
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combined with the hen’s egg test on the chorioallantoic membrane assay (HETCAM) covers
the whole spectrum of irritation, since mild or very mild irritation signs can be detected.
3.4.1. Bovine Corneal Opacity and Permeability Test (BCOP)
Transmittance values of opacity and permeability assays were studied to assess
whether formulations induce corrosivity or irritation (see Figures 10 and 11). No sig-
nificant structural changes were observed in terms of corneal opacity and fluorescein
permeability when comparing all formulations to the negative control solution (PBS) but
were observed with regard to the positive control (ethanol) (α < 0.05).
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All tacrolimus eyedrops were tested on the egg’s CAM as well as two controls, NaCl 
as a negative control (C-) and NaOH as a positive control (C+). All formulations were 
evaluated, and data were compared to the NaCl and NaOH solutions’ results. All formu-
lations showed no toxic effects (irritation score = 0) compared them with the positive con-
trol formulation (see Figure 12). This agrees with previously described BCOP test results. 
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Figure 1. Opacity values of bovine corneas treated with TBS 20, TLI 20, TBS 40, TLI 40, REF, PBS
(negative control) and ethanol (positive control) after 10 min tacrolimus formulation treatment and
120 min PBS treatment. Here, 63% light transmission corresponds to the total light transmitted
through bovine corneas incubated in PBS. Statistical analysis: one-way ANOVA followed by Tukey´s
multiple comparison test (* α < 0.05 compared with prepared formulations, reference formulation
and negative control).
Similarly, opacity and permeability data were corrected for background or control
values prior to furth r statistical de rminations being estimated. The IVIS score was
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then calculated and all formulations resulted in an in vitro irritation score of 0 (IVIS = 0),
showing no toxic effects compared to control formulations.
Likewise, the fluorescein permeability test was further applied on the corneas previ-
ously treated with the tested formulations. The resulting data showed no statistically sig-
nificant differences between all the formulations; however, significant differences (α < 0.05)
were observed between the studied formulation and the positive control (ethanol).
3.4.2. Hen’s Egg Test on the Chorioallantoic Membrane (HETCAM)
All tacrolimus eyedrops were tested on the egg’s CAM as well as two controls, NaCl
as a negative control (C-) and NaOH as a positive control (C+). All formulations were
evaluated, and data were compared to the NaCl and NaOH solutions’ results. All formula-
tions showed no toxic effects (irritation score = 0) compared them with the positive control
formulation (see Figure 12). This agrees with previously described BCOP test results.
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Figure 12. Hen’s e g test on the chorioallantoic i es 5 in post-instillation
for the different formulations. (a) NaCl ( -); (b TBS 20; (c) TLI 20; (d) TBS 40; (e) TLI 40; (f): REF; (g)
NaOH (C+).
3.5. Stability Study
Stability studies of pharmaceutical compounds are essential to ensure drug effi-
cacy [79,80] as well as to know if degradation products can cause toxic side effects and
other undesired effects [27]. In this assay, only TBS 40 and TLI 40 were studied due to all
formulations containing the exact same qualitative composition; thus, the formulations
with the highest tacrolimus concentrations were tested as representative; these formulations
were chosen based on the clinical common usability and the drug concentration similarity
at present. As presented in Figure 13, it can be seen that temperature was an important
factor in the stability under storage of tacrolimus/HPβCD ophthalmic formulations. TBS
40 and TLI 40 showed the same tacrolimus degradation pattern for each storage condition
and no statistically significant differences were found between them (α > 0.05).
Table 3 shows the degradation constant (K), expiration time (t90) and determination
coefficient (R2) values for both tacrolimus eye drops. It must be taken into account that
TBS 40 showed a higher degradation rate (1.23 times) than TLI 40 for the oven temperature
condition, though significant degradation rate variations were not observed for the other
two storage conditions.
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Figure 13. Tacrolimus concentration, pH and osmolality stability of (a) TBS 40 and (b) TLI 40 stored under three different
temperature conditions: in refrigeration (4 ± 2 ◦C), at room temperature (25 ± 2 ◦C) and at oven temperature (40 ± 2 ◦C)
during a 4-month stability test.
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Table 3. The degradation constant K, t90 and R2 of two tacrolimus eye drops (TBS 40 and TLI 40) obtained by interpolation
of the calculated regression line (% of remaining tacrolimus concentration vs time).
Formulations Storage Condition
K (days−1) t90 (days) R2
Mean SD Mean SD Mean SD
TBS 40
Refrigeration (4 ◦C) 0.0006 4.3 × 10−5 184.32 13.5 0.8890 0.0179
Room temperature (25 ◦C) 0.0067 0.0002 15.72 0.53 0.9645 0.0057
Oven temperature (40 ◦C) 0.0713 0.0016 1.48 0.03 0.9966 0.0012
TLI 40
Refrigeration (4 ◦C) 0.0011 5.8 × 10−5 98.50 5.2 0.9410 0.040
Room temperature (25 ◦C) 0.0067 0.0002 15.66 0.40 0.9867 0.0035
Oven temperature (40 ◦C) 0.0577 0.0004 1.82 0.01 0.9959 0.0007
Eye drops stored at oven temperature (40 ± 2 ◦C) were not stable in the first 7 days
of the study, observing a rapid tacrolimus degradation process. In the case of eye drops
kept at room temperature (25 ± 2 ◦C), the tacrolimus degradation was not so abrupt,
but from day 15 of the study, the tacrolimus concentration was reduced to below 90%
of the initial concentration, so the formulation was no longer stable. Nonetheless, both
eye drops preserved in refrigeration (4 ± 2 ◦C) were stable beyond the 3-month period;
specifically, the initial concentration of tacrolimus previously fell below 90% in the TLI 40
formulation compared to the TBS 40 formulation. Therefore, the optimal storage condition
for tacrolimus topical ophthalmic formulations was at 4 ◦C.
In this way, it was determined that eye drops kept in refrigeration condition have
an available period of at least 3 months. In the case of TLI 40, the presence of benzalko-
nium chloride may be beneficial to the stability of tacrolimus once opened by minimizing
microbial contamination.
Prajapati et al. studied tacrolimus degradation in aqueous HPβCD solutions [27].
Their results showed an inversely proportional correlation between tacrolimus degradation
rate and HPβCD concentration values, with a maximum degradation value where no
HPβCD was included into the formulations. The presence of 40% (w/v) HPβCD in the
formulations used in the present study suggested that the increased stability of tacrolimus
was due to the inclusion of complex formation between HPβCD and tacrolimus.
Likewise, pH and osmolality measurements showed no significant changes over the
course of the study regardless of storage condition (α > 0.05). The results guaranteed
that all tested formulations were also in the appropriate range for topical ophthalmic
administration, ensuring suitability for an accurate tacrolimus ocular penetration.
Furthermore, microbiological control growth is a test to take into account the quality
control of the prepared formulations since it ensures the sterility of the preparations and,
therefore, the conditions of asepsis in the production process. Sterility is one of the most im-
portant requirements when preparing ophthalmic formulations as it reduces the risk of eye
infections. In this study, an adequate conservation of the eye drops was observed for each
condition since no presence of microorganisms was found in any of the studied samples.
In addition, no macroscopic changes (e.g., color, turbidity and precipitation) were observed
during the whole study period. Thus, the absence of microorganisms and suspended
particles was in good agreement with the preparation of this type of topical ophthalmic
formulations in HPDs, by a simple technique with non-strict equipment requirements.
3.6. In Vivo Evaluation of the Residence Time on the Ocular Surface
The development of new ophthalmic topical vehicles for increasing drugs’ permanence
on the ocular surface is important to improve drug bioavailability in the eye as well as
the treatment adherence by patients [81]. PET/CT imaging is a relatively new imaging
modality that provides a quantifiable signal on the pharmacokinetic profile of the topically
administered radiopharmaceutical. In this way, it allows to obtain a signal in the eye after
an eye drop instillation and its subsequent follow-up at different study times, and to be
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able to follow the biodistribution of the formulation in the nasolacrimal duct and nasal
cavity [62].
In this study, the PET/CT imaging technique was used to determine the residence
times of the proposed tacrolimus topical ophthalmic formulations on the ocular surface,
and they were compared with the tacrolimus eye drop (REF) elaborated by HPDs.
In Figure 14, the permanence of the studied eye drops at different times can be
seen more visually, with PET/CT images showing both coronal planes (rat eyes and
nasolacrimal duct).
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TLI 40 formulations compared to TBS 20 and TLI 20; the best formulation result was ob-
tained for TLI 40. The results from the ocular permanence assays showed that formula-
tions containing higher concentrations of HPβCD had a longer eye residence time, regard-
less of the vehicle used. Adding HPβCD to formulations, apart from increasing the solu-
bility and stability of tacrolimus, also gave a more viscous and stickier characteristic to the 
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as it can be seen during eye drop instillation. PET/CT studies showed that the formula-
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Figure 14. Fused positron emission tomography (PET)/computed tomography (CT) images displayed in coronal plane
representing rat eyes (above) and nasolacrimal duct (below) with TBS 20, TLI 20, TBS 40, TLI 40 and REF at 0, 30, 75, 120,
240 and 300 minut s post-administration. The formulation signal on the eye surface is coded on a color scal : blue areas
show low radi active activity whereas red areas show high radioactive activity.
Figure 15 shows the clearance rate for each tested formulation compared to the
tacrolimus eye drop (REF) elaborated by HPDs. The clearance rate was represented in
terms of the ocular remaining radioactivity uptake over time after instillation and the
corresponding fits in order to estimate all pharmacokinetic parameters (K, t1/2, AUC0∞
and MRT) nd th emaining formulation at 75 min (%), which are represented in Table
4. All the parameters indicated a significant increase in the ocular retention time for the
TBS 40 and TLI 40 formulations compared to TBS 20 and TLI 20; the best formulation
result was obtained for TLI 40. The results from the ocular permanence assays showed that
formulations containing higher concentrations of HPβCD had a longer eye residence time,
regardless f the vehicle used. Adding HPβCD to formulations, ap rt from increasing the
solubility and stability of tacrolimus, also gav a more viscous and stickier characteristic to
the solution. This feature helps the eye drop to spread and be more retained on the eye
surface as it can be seen during eye drop instillation. PET/CT studies showed that the
formulations were mucoadhesive and had an adequate consistency to remain on the ocular
surface for a long time.
A two-way ANOVA was applied t the % of remaining formulation on the ocular
surface parameter in order to evaluate the influence of the time and the formulation
in its clearance to determine whether there were differences in the permanence of the
formulations on the corneal surface. No statistically significant differences were observed
between 20% (w/v) HPβCD formulations compared to REF. Nevertheless, statistically
significant ifferences were observed (α < 0.05) between 20% (w/v) HPβCD formulations
and 40% (w/v) HPβCD formulations as well as between 40% (w/v) HPβCD formulations
and REF for times beyond 30 min post-administration.
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uptake (%) vs time after instillation. 
A two-way ANOVA was applied to the % of remaining formulation on the ocular 
surface parameter in order to evaluate the influence of the time and the formulation in its 
clearance to determine whether there were differences in the permanence of the formula-
tions on the corneal surface. No statistically significant differences were observed between 
20% (w/v) HPβCD formulations compared to REF. Nevertheless, statistically significant 
differences were observed (α < 0.05) between 20% (w/v) HPβCD formulations and 40% 
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Table 4. Pharmacokinetics parameters (K, t1/2, AUC0∞, mean residence time (MRT) and % remaining formulation at 75 min) 
of the tacrolimus eye drops obtained by the fitting of the percentage formulation remaining on ocular surface. 
Formulations 
K (min−1) t1/2 (min) AUC0∞ (% × min) MRT (min) Remaining Formulation at 75 min (%) 
Mean SD Mean SD Mean SD Mean SD Mean SD 
TBS 20 0.014 0.003 49.70 10.34 74.96 7.70 72.90 6.02 31.99 12.79 
TLI 20 0.025 0.008 29.40 8.51 59.16 11.18 73.94 22.62 17.79 3.74 
TBS 40 0.024 0.023 61.79 46.16 89.61 57.41 76.43 35.70 57.46 19.65 
TLI 40 0.011 0.007 86.22 38.93 123.31 51.18 90.51 17.67 78.82 11.15 
REF 0.018 0.010 46.34 22.88 82.22 30.2 93.28 37.55 27.44 15.65 
The TLI 40 vehicle (Liquifilm®) is composed of PVA; this polymer has a mechanism 
based on the interdiffusion of polymer chains across the bioadhesive interface that pro-
duces entanglements and physical bonds between the polymer and the substrate. The in-
timate contact and the presence of hydroxyl radicals in the polymer can promote the es-
tablishment of weak interactions with the mucin layer (i.e., hydrogen bonds) [82]. The 
mucoadhesion study assumptions related to TLI 40 formulation were confirmed by the 
PET/CT imaging technique. 
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Figure 15. Tacrolimus eyedrop clearance rate (TBS 20, TLI 20, TBS 40, TLI 40 and REF) from the
ocular surface determined by PET. Resulting data are represented in eye remaining radioactivity
uptake (%) vs time after instillation.
Table 4. Pharmacokinetics parameters (K, t1/2, AUC0∞, mean residence time (MRT) and % remaining formulation at 75 min)
of the tacrolimus eye drops obtained by the fitting of the percentage formulation remaining on ocular surface.
Formulations





Mean SD Mean SD Mean SD Mean SD Mean SD
TBS 20 0.014 0.003 49.70 10.34 74.96 7.70 72.90 6.02 31.99 12.79
TLI 20 0.025 0.008 29.40 8.51 59.16 11.18 73.94 22.62 17.79 3.74
TBS 40 0.024 0.023 61.79 46.16 89.61 57.41 76.43 35.70 57.46 19.65
TLI 40 0.011 0.007 86.22 38.93 123.31 51.18 90.51 17.67 78.82 11.15
REF 0.018 0.010 46.34 22.88 82.22 30.2 93.28 37.55 27.44 15.65
The TLI 40 vehicle (L quifilm®) is composed of PVA; this polymer has a mechanism
based on the interdiffusion of polymer chains across the bioadhesive interface that pro-
duces entanglements and physical bonds between the polymer and the substrate. The
intimate contact and the presence of hydroxyl radicals in the polymer can promote the
establishment of weak interactions with the mucin layer (i.e., hydrogen bonds) [82]. The
mucoadhesion study assumptions related to TLI 40 formulation were confirmed by the
PET/CT imaging technique.
The conventional pharmacological treatments for uveitis are associated with strict
patient compliance, limited efficacy due to the appearance of refractory processes and
different severe side effects. HPDs have resorted to a reformulation process of intravenous
formulations as a way to obtain new topical ophthalmic pharmacy compounding as a
pharmacological alternative. One of the most used pharmacy compounding products was
based on Prograf® reformulation, this being an hydroalcoholic eye drop containing 0.03%
(w/v) tacrolimus. Nevertheless, this type of treatment has shown different disadvantages,
including high osmolality and patient discomfort due to the eye drop composition.
Different formulations are proposed in the present work as new pharmacological al-
ternatives, specifically intended for topical ophthalmic administration for uveitis treatment.
These formulations have proven to be adequate for this administration pathway, showing
several advantages compared to the currently used treatments, including I) patient comfort
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improvement, II) great efficacy with a simple preparation method, III) easy translational
research to HPDs and IV) a health expenditure reduction in uveitis treatment.
4. Conclusions
In this work, a consistent tacrolimus solubilization study was carried out as a way
to deeply understand this drug behavior in future topical ophthalmic formulations.
Tacrolimus/HPβCD interaction in solution was confirmed by phase solubility diagram,
NMR and molecular modeling studies, and the influence of the vehicle was also studied.
The use of 40% (w/v) HPβCD allowed to prepare eye drop solutions with a 0.02% (w/v)
tacrolimus concentration that could be in the therapeutic range for uveitis treatment.
The developed HPβCD-based formulations showed pH, osmolality, surface tension
and safety values in the optimum range for topical ophthalmic administration. Stabil-
ity studies showed no changes in the eye drops kept in refrigeration condition for at
least 3 months, which could facilitate the preparation programming and improve the
patient comfort.
Additionally, ex vivo mucoadhesion and in vivo ocular permanence studies showed
good mucoadhesive properties and lower ocular clearance for TBS 40 and TLI 40, al-
most doubling the permanence half-life time in the ocular surface compared to the REF
pharmacy compounding.
Taking into account all of the obtained results, TLI 40 was proposed as the best
candidate. This eye drop allowed reaching a 0.02% (w/v) drug dose, which was safe
and showed the best mucoadhesive and ocular permanence properties. In addition, the
presence of benzalkonium chloride in Liquifilm® could help to prevent microbial growth
once the eye drops were opened.
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